论文部分内容阅读
Objective: The present study aimed to investigate the efficacy of Shenfu injection plus vinorelbine on the promotion of the quality of life (QOL) in elderly non-small cell lung cancer (NSCLC) patients. Methods: A randomized single blind trial method was used. Forty-six patients with stage IIIB–IV of NSCLC were randomly divided into experimental group and control group. In the experimental group, the patients were treated with 50 mL Shenfu injection from day 1 to 14, plus vinorelbine (NVB) 25 mg/m2 on day 1 and 8. In the control group, the patients were only treated with NVB 25 mg/m2 on day 1 and 8. After two cycle’s of treatment, QOL, efficacy and toxicity were observed. Results: The QOL was enhanced in both experimental group and control group. However, the difference of KPS after treatment in the experimental group was markedly higher than in the control group (14 ± 10 vs. 8 ± 10, t = 2.116, P = 0.04), improvement rate of QOL was better than in the control group (76.2% vs. 45.0%, χ2 = 4.188, P = 0.041), treatment related toxicity in the experimental group was also markedly lower than in the control group (χ2 = 3.866, P = 0.049), but the difference of efficacy between the two groups was not significant (14.3% vs. 15.0%, χ2 = 0.161, P = 0.688). Conclusion: Shenfu injection plus vinorelbine can enhance QOL in elderly NSCLC patients.
Objective: The present study aimed to investigate the efficacy of Shenfu injection plus vinorelbine on the promotion of the quality of life (QOL) in elderly non-small cell lung cancer (NSCLC) patients. Methods: A randomized single blind trial method was used. The experimental group, the patients were treated with 50 mL Shenfu injection from day 1 to 14, plus vinorelbine (NVB) 25 mg / m2 on day 1 and 8. In the control group, the patient were only treated with NVB 25 mg / m2 on day 1 and 8. After two cycle’s of treatment, QOL, efficacy and toxicity were observed. Results: The QOL was enhanced in both experimental group and control group. However, the difference of KPS after treatment in the experimental group was markedly higher than in the control group (14 ± 10 vs. 8 ± 10, t = 2.116, P = 0.04), improvement rate of QOL was better than in the control group (76.2% vs. 45.0 %, χ2 = 4.188, P = 0.041), treatment related toxicity in the experimental group was also markedly lower than in the control group (χ2 = 3.866, P = 0.049), but the difference of efficacy between the two groups was not significant ( 14.3% vs. 15.0%, χ2 = 0.161, P = 0.688). Conclusion: Shenfu injection plus vinorelbine can enhance QOL in elderly NSCLC patients.